Clinical Trial Update: Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and immunogenicity of the MVA-based CMV vaccine Triplex has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infections
• HIV Infections

Drugs mentioned

• Triplex CMV Vaccine

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Cytomegalovirus Infections, HIV Infections | Phase 2 | Status: COMPLETED